ArticleEuropean journal of pediatrics2026
Predictive value of quantitative NS1 antigen, IgM and IgG antibody titres in assessing dengue severity in children.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objectives of the study are to evaluate whether quantitative NS1 antigen and IgM/IgG antibody titres predict clinical severity in paediatric dengue and to determine whether the IgM/IgG ratio reliably differentiates primary from secondary infection. A 1-year cross-sectional study was conducted at a tertiary care centre in South India, enrolling children aged 1 month to 18 years with laboratory-confirmed dengue. Quantitative NS1 antigen, IgM, and IgG titres were measured at point-of-care and correlated with clinical outcomes. Severity indices included bleeding manifestations, third spacing, thrombocytopenia, hepatic and renal involvement, shock, and duration of hospitalization. Statistical analysis was performed using chi-square and Mann-Whitney U tests, with receiver operating characteristic (ROC) and area under the ROC curve (AUROC) analyses using IBM SPSS version 29. High NS1 titres (60-100 and ≥ 100) were significantly associated with bleeding, renal dysfunction, elevated SGOT, haemoconcentration, and thrombocytopenia. IgM titres < 4 correlated strongly with third spacing (82.1%, p = 0.019), while IgG titres ≥ 35 predicted third spacing (75%), thrombocytopenia, and elevated transaminases. An IgM/IgG ratio < 0.85 differentiated secondary dengue with superior sensitivity and specificity compared with higher cutoffs (AUROC 0.793). Infantile dengue demonstrated greater severity, with hypoalbuminemia (62%) and central nervous system involvement (25%), despite lower NS1 detection rates, and showed reversal of the typical SGOT > SGPT pattern.
conclusionQuantitative NS1 antigen and IgM/IgG antibody titres provide early severity-predictive information in paediatric dengue. An IgM/IgG ratio < 0.85 reliably identifies secondary infection. Incorporating these markers into routine clinical evaluation may enhance early risk stratification, particularly in resource-limited settings. WHAT IS KNOWN: • NS1 antigen and IgM/IgG antibody titters are widely used for diagnosis, and IgM/IgG ratio is commonly used to classify primary versus secondary dengue. • Dengue severity is higher in secondary infection and is usually assessed using haemoconcentration, thrombocytopenia, and clinical warning signs which often appear late. WHAT IS NEW: • Quantitative titters-High NS1 and low IgM antibody titres predict paediatric dengue severity early, allowing identification of high-risk children at presentation. • Infants show lower NS1 titters but higher severity; IgG titres in secondary dengue do not correlate with day of illness; an IgM/IgG ratio < 0.85 outperforms higher cutoffs (1.59) in identifying secondary dengue.
Indexed as
Identifiers
42047860What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.